The Bombay High Court has criticized the Maharashtra FDA for procedural lapses in cancelling Cipla Pharma's license. The court ordered the immediate withdrawal of the impugned order, citing a violation of natural justice.

  • Bombay High Court slammed the Maharashtra FDA for "going overboard" in its regulatory actions.
  • The order cancelling Cipla Pharma's license is to be withdrawn immediately.
  • The court highlighted that a hearing notice was issued on a state holiday, violating transparency norms.
  • Fresh notices must be served to Cipla Pharma by September 4.

The Bombay High Court on Saturday delivered a stern reprimand to the Maharashtra Food and Drug Administration (FDA) regarding the cancellation of Cipla Pharma's license. The bench questioned the transparency and fairness of the regulatory body, noting that the authority had acted in a high-handed manner.

The controversy stems from an inspection conducted in June, where FDA officials allegedly discovered irregularities in the packaging and advertising materials of certain tablets manufactured by Cipla. Following these findings, the FDA proceeded to cancel the company's license, a move that was subsequently challenged in court.

Read Also:Punjab Teen and Friend Die After Consuming Poison Over Online Gaming Losses

Judicial Scrutiny of Regulatory Conduct

Acting Chief Justice Ravindra V. Ghuge expressed significant concern over the timing of the regulatory proceedings. "Notice of hearing was given on August 26 on a state holiday, and your office was not open. How is this appropriate, fair, and transparent?" the judge remarked, adding that while the FDA does commendable work, it was "working overboard."

The bench, which also included Justice Gautam A. Ankhad, focused on the principle of natural justice. The court questioned how the department's order could be sustainable when the fundamental right to a fair hearing was compromised by scheduling proceedings on a non-working day.

Why This Matters

BozokMedia analysis shows that this ruling sets a critical precedent for regulatory accountability in India. When state agencies bypass standard operating procedures—such as conducting hearings on holidays or failing to provide adequate notice—it undermines the legal framework and creates uncertainty for large-scale pharmaceutical manufacturers operating within the country.

Justice must not only be done, but must appear to be done; procedural integrity is the bedrock of regulatory authority.

Following the intense questioning, the state lawyer, acting on instructions from FDA officials, informed the bench that the impugned order would be withdrawn forthwith. The court has directed the FDA to serve fresh notices to Cipla Pharma before September 4, allowing the company to submit a detailed reply by September 11.

Historical Background

Regulatory bodies like the FDA are tasked with maintaining stringent standards for drug safety and advertising. However, legal battles regarding the 'Right to be Heard' under administrative law are frequent. Courts consistently intervene when regulatory bodies fail to follow the 'audi alteram partem' principle (hear the other side) during disciplinary actions.

Did You Know?: In administrative law, the principle of 'Natural Justice' ensures that no person is judged without a fair opportunity to defend themselves.

Frequently Asked Questions

1. Why did the FDA cancel Cipla's license?
The FDA cited irregularities in the packaging and advertising materials of certain tablets found during a June inspection.

2. What was the main error made by the FDA?
The primary error was issuing a hearing notice on a state holiday, which prevented a fair and transparent hearing.